Cargando…

High-level resistance to non-nucleos(t)ide reverse transcriptase inhibitor based first-line antiretroviral therapy in Ghana; A 2017 study

Expanding access to effective antiretroviral therapy (ART) is a major tool for management of Human Immunodeficiency Virus (HIV) infection. However, rising levels of HIV drug-resistance have significantly hampered the anticipated success of ART in persons living with HIV (PLWH), particularly those fr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parbie, Prince Kofi, Abana, Christopher Zaab-Yen, Kushitor, Dennis, Asigbee, Theodore Worlanyo, Ntim, Nana Afia Asante, Addo-Tetebo, Gifty, Ansong, Maclean Richard Darko, Ofori, Sampson Badu, Mizutani, Taketoshi, Runtuwene, Lucky Ronald, Nishizawa, Masako, Ishikawa, Koichi, Kiyono, Hiroshi, Ampofo, William Kwabena, Matano, Tetsuro, Bonney, Evelyn Yayra, Kikuchi, Tadashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459847/ https://www.ncbi.nlm.nih.gov/pubmed/36090108 http://dx.doi.org/10.3389/fmicb.2022.973771

Ejemplares similares

Dysbiotic Fecal Microbiome in HIV-1 Infected Individuals in Ghana
por: Parbie, Prince Kofi, et al.
Publicado: (2021)

Community based multi-disease health screening as an opportunity for early detection of HIV cases and linking them to care
por: Abana, Christopher Z-Y., et al.
Publicado: (2023)

Gut microbiota signature of pathogen-dependent dysbiosis in viral gastroenteritis
por: Mizutani, Taketoshi, et al.
Publicado: (2021)

Transmitted drug resistance mutations and subtype diversity amongst HIV-1 sero-positive voluntary blood donors in Accra, Ghana
por: Obeng, Billal Musah, et al.
Publicado: (2020)

Emergence of HIV-1 drug resistance mutations in mothers on treatment with a history of prophylaxis in Ghana
por: Martin-Odoom, Alexander, et al.
Publicado: (2018)

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
por: Jung, Sang Kyung, et al.
Publicado: (2015)

HIV cure strategies: which ones are appropriate for Africa?
por: Abana, Christopher Zaab-Yen, et al.
Publicado: (2022)

Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B
por: Kim, Soon Sun, et al.
Publicado: (2011)

The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs
por: Gupta, Nidhi, et al.
Publicado: (2014)

Durability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis B
por: Lee, I-Cheng, et al.
Publicado: (2015)

Selected nucleos(t)ide-based prescribed drugs and their multi-target activity
por: Pastuch-Gawołek, Gabriela, et al.
Publicado: (2019)

Management of chronic hepatitis B patients: Efficacy & limitation of nucleos(t)ide analogues
por: Inoue, Jun, et al.
Publicado: (2011)

The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis
por: Cholongitas, Evangelos, et al.
Publicado: (2015)

Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?
por: Moreno-Cubero, Elia, et al.
Publicado: (2018)

Distinct histological patterns in chronic hepatitis D with nucleos(t)ide analogue therapy
por: Hercun, Julian, et al.
Publicado: (2023)

Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B
por: Sonneveld, Milan J., et al.
Publicado: (2010)

Nucleos(t)ide analogues treatment outcome in genotype B and C chronic hepatitis B
por: Aung, Myo Nyein, et al.
Publicado: (2010)

Impact of nucleos(t)ide analog treatment on the development of malignancy in patients with chronic hepatitis B
por: Kim, Soon Sun, et al.
Publicado: (2018)

Antiviral Efficacy of Tenofovir Monotherapy in Children with Nucleos(t)ide-naive Chronic Hepatitis B
por: Choe, Jae Young, et al.
Publicado: (2017)

Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review
por: de Fraga, Raquel Scherer, et al.
Publicado: (2020)

Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B
por: Roade, Luisa, et al.
Publicado: (2021)

Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs
por: Siakavellas, Spyros, et al.
Publicado: (2021)

Platinum-Nucleos(t)ide Compounds as Possible Antimetabolites for Antitumor/Antiviral Therapy: Properties and Perspectives
por: De Castro, Federica, et al.
Publicado: (2023)

Super high-resolution single-molecule sequence-based typing of HLA class I alleles in HIV-1 infected individuals in Ghana
por: Nii-Trebi, Nicholas I., et al.
Publicado: (2022)

Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients
por: Kim, Young Jip, et al.
Publicado: (2013)

Comparison of the Efficacy of Entecavir and Tenofovir in Nucleos(T)ide Analogue-Experienced Chronic Hepatitis B Patients
por: Cho, Eun Ju, et al.
Publicado: (2015)

An evaluation of entecavir treatment among nucleos(t)ide-naïve Moroccan patients with chronic hepatitis B
por: Chakkor, Amal, et al.
Publicado: (2016)

Gemcitabine and Nucleos(t)ide Synthesis Inhibitors Are Broad-Spectrum Antiviral Drugs that Activate Innate Immunity
por: Shin, Hye Jin, et al.
Publicado: (2018)

Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B
por: Papatheodoridi, Margarita, et al.
Publicado: (2020)

Nucleos(t)ide analogues and Hepatitis B virus-related hepatocellular carcinoma: A literature review
por: Abd El Aziz, Mohamed A, et al.
Publicado: (2020)

Current Perspectives on Nucleos(t)ide Analogue Therapy for the Long-Term Treatment of Hepatitis B Virus
por: Broquetas, Teresa, et al.
Publicado: (2022)

Predictors of Sustained Virologic Response after Discontinuation of Nucleos(t)ide Analog Treatment for Chronic Hepatitis B
por: Peng, Jie, et al.
Publicado: (2015)

Kushenin Combined with Nucleos(t)ide Analogues for Chronic Hepatitis B: A Systematic Review and Meta-Analysis
por: Chen, Zhe, et al.
Publicado: (2015)

High percentage atypical hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs
por: Lin, Ching-Chung, et al.
Publicado: (2019)

Combination of Pegylated Interferon and Nucleos(t)ide Therapy: Toward a Cure of Hepatitis B Virus Infection?
por: Cho, Eun Ju, et al.
Publicado: (2016)

Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same?
por: Yip, Terry Cheuk-Fung, et al.
Publicado: (2020)

Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score
por: Kaneko, Shun, et al.
Publicado: (2020)

Impact of antiviral therapy with nucleos(t)ide analog on survival of patients with HBV-related small hepatocellular carcinomas
por: Wei, Yanyan, et al.
Publicado: (2019)

Clinical features of hepatocellular carcinoma with hepatitis B virus among patients on Nucleos(t) ide analog therapy
por: Liu, Li
Publicado: (2020)

Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV/HDV co-infected patients
por: Scheller, Laura, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ukni6dknoqhptug9g21da846ai